Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Type I Diabetes
100%
Type 1 Diabetes Mellitus (T1DM)
100%
Randomized Trial
100%
Recent-onset
100%
Antithymocyte Globulin
100%
Placebo
53%
Thymoglobulin
26%
New-onset Type 1 Diabetes
20%
T Cell Subsets
13%
C-peptide
13%
Islet Function
13%
Randomized Placebo-controlled Trial
6%
Opportunistic Infections
6%
Long-term Safety
6%
Data Coordinating Center
6%
Long-term Efficacy
6%
Management Team
6%
Infectious Diseases
6%
Regulatory Cells
6%
Childrens
6%
B Cells
6%
Diabetes Management
6%
Safety Response
6%
Healthcare Team
6%
Immunological Response
6%
Older Patients
6%
Unblinding
6%
Immune Signaling
6%
T-cell Mediated
6%
University Medical Centre
6%
Adverse Events
6%
Tetanus
6%
Drug Administration
6%
Infection Rate
6%
National Institutes of Health
6%
Humoral Immune Response
6%
Trial Registration
6%
Older Participants
6%
Circulating T Cells
6%
Public Data Repositories
6%
Permuted Block
6%
Central Memory
6%
Allergy Disease
6%
Randomization Scheme
6%
Memory Subsets
6%
Stratified Randomization
6%
Stimulated C-peptide
6%
C-peptide Secretion
6%
Beta Cell Autoantibodies
6%
Placebo Groups
6%
Medicine and Dentistry
Insulin Dependent Diabetes Mellitus
100%
Thymocyte Antibody
100%
Placebo
52%
C-Peptide
21%
Infection
15%
Beta Cell
10%
T Cell Subset
10%
T Cell
5%
Diabetes
5%
Opportunistic Infection
5%
Patient Care
5%
Immunological Tolerance
5%
Tetanus
5%
Secretion (Process)
5%
Regulatory Cell
5%
Adverse Event
5%
Infectious Disease
5%
Drug Administration
5%
Post-Hoc Analysis
5%
Humoral Immunity
5%
Autoantibodies
5%
Immunology and Microbiology
Anti-Thymocyte Globulin
100%
Peptides
21%
Infection
15%
T Cell Subset
10%
Immune Tolerance
5%
Autoantibodies
5%
Humoral Immunity
5%
Regulatory Cell
5%
Secretion (Process)
5%
T Cell
5%
Opportunistic Infection
5%